$21.45
0.23% yesterday
Nasdaq, Nov 15, 03:53 pm CET
ISIN
US98978N2009
Symbol
ZIVO
Sector
Industry

Zivo Bioscience Inc Stock price

$21.45
+1.45 7.25% 1M
+13.47 168.80% 6M
+20.25 1,687.50% YTD
+20.05 1,432.14% 1Y
-1.11 4.92% 3Y
-19.35 47.43% 5Y
-26.55 55.31% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.05 0.23%
ISIN
US98978N2009
Symbol
ZIVO
Sector
Industry

Key metrics

Market capitalization $76.01m
Enterprise Value $76.59m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1,276.50
P/S ratio (TTM) P/S ratio 1,266.83
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 1,364.69%
Revenue (TTM) Revenue $60.00k
EBIT (operating result TTM) EBIT $-12.97m
Free Cash Flow (TTM) Free Cash Flow $-5.01m
Cash position $0.00
EPS (TTM) EPS $-5.26
P/E forward negative
P/S forward 136.25
EV/Sales forward 138.21
Short interest 2.61%
Show more

Is Zivo Bioscience Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Zivo Bioscience Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Zivo Bioscience Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Zivo Bioscience Inc:

Buy
100%

Financial data from Zivo Bioscience Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.06 0.06
-
100%
- Direct Costs 0.04 0.04
50% 50%
67%
0.02 0.02
125% 125%
33%
- Selling and Administrative Expenses 9.90 9.90
57% 57%
16,500%
- Research and Development Expense 3.10 3.10
57% 57%
5,167%
-13 -13
55% 55%
-21,617%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -13 -13
54% 54%
-21,624%
Net Profit -13 -13
52% 52%
-22,083%

In millions USD.

Don't miss a Thing! We will send you all news about Zivo Bioscience Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zivo Bioscience Inc Stock News

Neutral
Business Wire
3 months ago
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens. The study, which was conducted in collab...

Company Profile

Zivo Bioscience, Inc. engages in the study, development, and commercialization of natural nutritional compounds and bioactive molecules. It offers proprietary algae strain, extracts and supernatants, and bioactive compounds. The company was founded by Howard R. Baer on March 28, 1983 and is headquartered in Keego Harbor, MI.

Head office United States
CEO John Payne
Employees 8
Founded 1983
Website www.zivobioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today